LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4587-4597

  Aoyama, Mineyoshi ^a   Ozaki, Toshinori ^a   Inuzuka, Hiroyuki ^a   Tomotsune, Daihachiro ^a   Hirato, Junko ^b   Okamoto, Yoshiaki ^a   Tokita, Hisashi ^a   Ohira, Miki ^a   Nakagawara, Akira ^a,c  

^a HISAMITSU PHARMACEUTICAL CO INC   (Japan)

^b GUNMA UNIVERSITY   (Japan)

^c CHIBA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HELIX LOOP HELIX PROTEIN; LIM PROTEIN; PROTEIN LMO3; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HEN2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL NUCLEUS; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MOUSE; NERVE CELL; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH;

AMINO ACID SEQUENCE; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; INFANT; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEUROBLASTOMA; ONCOGENE PROTEINS; ONCOGENES; TRANSFECTION;

EID: 19644363959     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4630     Document Type: Article

References (42)

1. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adaptors and functional modifiers in protein interactions. Trends Genet 1998;14:156-62.
2. Sanchez-Garcia I, Rabbitts TH. The LIM domain: a new structural motif found in zinc-finger-like proteins. Trends Genet 1994;10:315-20.
3. Dawid IB, Toyama R, Taira M. LIM domain proteins. C R Acad Sci III 1995;318:295-306.
4. Rabbitts TH. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. Genes Dev 1998;12:2651-7.
5. McGuire EA, Rintoul CE, Sclar GM, Korsmeyer SJ. Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/lymphoma. Mol Cell Biol 1992;12:4186-96.
6. Fisch P, Boehm T, Lavenir I, et al. T-cell acute lymphoblastic lymphoma induced in transgenic mice by the RBTN1 and RBTN2 LIM-domain genes. Oncogene 1992;7:2389-97.
7. Neale GA, Rehg JE, Goorha RM. Disruption of T-cell differentiation precedes T-cell tumor formation in LMO-2 (rhombotin-2) transgenic mice. Leukemia 1997;3:289-90.
8. Kenny DA, Jurata LW, Saga Y, Gill GN. Identification and characterization of LMO4, an LMO gene with a novel pattern of expression during embryogenesis. Proc Natl Acad Sci U S A 1998;95:11257-62.
9. Visvader JE, Venter D, Hahm K, et al. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci U S A 2001;98:14452-7.
10. Sum EY, Peng B, Yu X, et al. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J Biol Chem 2002;277:7849-56.
11. Foroni L, Boehm T, White L, et al. The rhombotin gene family encode related LIM-domain proteins whose differing expression suggests multiple roles in mouse development. J Mol Biol 1992;226:747-61.
12. Wadman I, Li J, Bash RO, et al. Specific in vivo association between the bHLH and LIM proteins implicated in human T cell leukemia EMBO J 1994;13:4831-9.
13. Larson RC, Lavenir I, Larson TA, et al. Protein dimerization between Lmo2 (Rbtn2) and Tall alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J 1996;15:1021-7.
14. Brown L, Espinosa R III, Le Beau MM, Siciliano MJ, Baer R. HEN1 and HEN2: a subgroup of basic helix-loop-helix genes that are coexpressed in a human neuroblastoma. Proc Natl Acad Sci U S A 1992;89:8492-6.
15. Begley CG, Lipkowitz S, Gobel V. et al. Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system. Proc Natl Acad Sci U S A 1992;89:38-42.
16. Brodeur GM, Azar C, Brother M, et al. Effect of genetic factors on prognosis and treatment. Cancer 1992;70:1685-94.
17. Brodeur GM, Nakagawara A. Molecular basis of clinical heterogeneity in neuroblastoma. J Pediatr Hematol Oncol 1992;14:111-6.
18. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4.
19. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6.
20. Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992;52:1364-8.
21. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993;328:847-54.
22. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D, Beck D. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 1994;54:4238-42.
23. Berwanger B, Hartmann O, Bergmann E, et al. Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma. Cancer Cell 2002;2:377-86.
24. Ohira M, Morohashi A, Inuzuka H. et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003;22:5525-36.
25. Ohira M, Shishikura T, Kawamoto T, et al. Hunting the subset-specific genes of neuroblastoma: expression profiling and differential screening of the full-length-enriched oligo-capping cDNA libraries. Med Pediatr Oncol 2000;35:547-9.
26. Brodeur GM, Pritchard J. Berthold F, et al. Revisions of the international criteria for neurobiastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
27. Matsumura T, Iehara T, Sawada T, Tsuchida Y. Prospective study for establishing the optimal therapy of infantile neuroblastoma in Japan. Med Pediatr Oncol 1998;31:210.
28. Kaneko M, Nishihira H, Mugishima H, et al.; Study Group of Japan for Treatment of Advanced Neuroblastoma, Tokyo, Japan. Stratification of treatment of stage 4 neuroblastoma patients based on N-myc amplification status. Med Pediatr Oncol 1998;31:1-7.
29. Takihara Y, Tomotsune D, Shirai M, et al. Targeted disruption of the mouse homologue of the Drosophila polyhomeotic gene leads to altered anteroposterior patterning and neural crest defects. Development 1997;124:3673-82.
30. Agulnick AD, Taira M, Breen JJ, Tanaka T, Dawid IB, Westphal H. Interactions of the LIM-domain-binding factor Ldb1 with LIM homeodomain proteins. Nature 1996;384:270-2.
31. Jurata LW, Kenny DA, Gill GN. Nuclear LIM interactor, a rhombotin and LIM homeodomain interacting protein, is expressed early in neuronal development Proc Natl Acad Sci U S A 1996;93:11693-8.
32. Bach I, Carriere C, Ostendorff HP, Andersen B, Rosenfeld MG. A family of LIM domain-associated cofactors confer transcriptional synergism between LIM and Otx homeodomain proteins. Genes Dev 1997;11:1370-80.
33. Osada H, Grutz G, Axelson H, Forster A, Rabbitts TH. Association of erythroid transcription factors: complexes involving the LIM protein RBTN2 and the zinc-finger protein GATA1. Proc Natl Acad Sci U S A 1995;92:9585-9.
34. Valge-Archer VE, Osada H, Warren AJ, et al. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Proc Natl Acad Sci U S A 1994;91:8617-21.
35. Bao J, Talmage DA, Role LW, Gautier J. Regulation of neurogenesis by interactions between HEN1 and neuronal LMO proteins. Development 2000;127:425-35.
36. Ono Y, Fukuhara N, Yoshie O. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. J Biol Chem 1997;272:4576-81.
37. Aplan PD, Jones CA, Chervinsky DS, et al. An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with to generate T-cell malignancies in transgenic mice. EMBO J 1997;16:2408-19.
38. Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002;62:1802-8.
39. Ono Y, Fukuhara N, Yoshie O. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. Mol Cell Biol 1998;18:6939-50.
40. Lutz W, Stohr M, Schurmann J, Wenzel A, Lohr A, Schwab M. Conditional expression of N-myc in human neuroblastoma cells increases expression of α-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 1996;13:803-12.
41. Schuldiner O, Benvenisty N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene 2001;20:4984-94.
42. Shohet JM, Hicks MJ, Pion SE, et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002;62:1123-8.